These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3976926)

  • 1. Psychopharmacologic and clinical correlates of attention in chronic schizophrenia.
    Strauss ME; Lew MF; Coyle JT; Tune LE
    Am J Psychiatry; 1985 Apr; 142(4):497-9. PubMed ID: 3976926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients.
    Tune LE; Strauss ME; Lew MF; Breitlinger E; Coyle JT
    Am J Psychiatry; 1982 Nov; 139(11):1460-2. PubMed ID: 6127957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
    Goff DC; Henderson DC; Amico E
    Am J Psychiatry; 1992 Sep; 149(9):1189-94. PubMed ID: 1503131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Performance and drugs. Activation, coordination, concentration and control as pharmacologic effects].
    Debus G
    Arch Psychol (Frankf); 1988; 140(4):247-59. PubMed ID: 3075446
    [No Abstract]   [Full Text] [Related]  

  • 5. Painful sensory symptoms in neuroleptic-induced extrapyramidal syndromes.
    Decina P; Mukherjee S; Caracci G; Harrison K
    Am J Psychiatry; 1992 Aug; 149(8):1075-80. PubMed ID: 1353315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amineptine treatment of persistent catatonic symptoms in schizophrenia: a controlled study.
    Ungvari GS
    Neuropsychopharmacol Hung; 2010 Dec; 12(4):463-7. PubMed ID: 21220791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Memory deficits and anticholinergic levels in chronic schizophrenia.
    Perlick D; Stastny P; Katz I; Mayer M; Mattis S
    Am J Psychiatry; 1986 Feb; 143(2):230-2. PubMed ID: 3946662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects.
    Tune L; Coyle JT
    Arch Gen Psychiatry; 1980 Mar; 37(3):293-7. PubMed ID: 6102457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol.
    Altamura AC; Buccio M; Colacurcio F; Colombo G; Terzi A
    Acta Neurol (Napoli); 1986 Feb; 8(1):19-26. PubMed ID: 3962752
    [No Abstract]   [Full Text] [Related]  

  • 11. Clozapine, negative symptoms, and extrapyramidal side effects.
    Kane JM; Safferman AZ; Pollack S; Johns C; Szymanski S; Kronig M; Lieberman JA
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():74-7. PubMed ID: 7961579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of alcohol and other drugs on psychomotor performance and cognitive function.
    Hindmarch I; Kerr JS; Sherwood N
    Alcohol Alcohol; 1991; 26(1):71-9. PubMed ID: 1854375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifts in covert visual attention in schizophrenic patients and normal controls.
    Moran MJ; Thaker GK; Smith D; Cassady S; Layne-Gedge J
    Biol Psychiatry; 1992 Oct; 32(7):617-20. PubMed ID: 1450288
    [No Abstract]   [Full Text] [Related]  

  • 14. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
    Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
    Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alcohol, drugs and traffic laws. 2: Studies of the assessment of significant disability in automobile driving fitness caused by psychotropic drugs or alcohol and psychotropic drug combinations].
    Eulitz J; Krause D; Herold C; Brier C; Koch R
    Z Arztl Fortbild (Jena); 1986; 80(19):823-6. PubMed ID: 3811420
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of depot neuroleptics on driving performance in chronic schizophrenic patients.
    Wylie KR; Thompson DJ; Wildgust HJ
    J Neurol Neurosurg Psychiatry; 1993 Aug; 56(8):910-3. PubMed ID: 8102393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients.
    Elizur A; Segal S; Yeret A; Ben-David M
    Isr Ann Psychiatr Relat Discip; 1979 Dec; 17(4):318-27. PubMed ID: 44877
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of novel antipsychotic drugs.
    Raleigh F
    Pharmacotherapy; 1996; 16(6 Pt 2):160S-165S; discussion 166S-168S. PubMed ID: 8948000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.
    Jahn T; Hubmann W; Karr M; Mohr F; Schlenker R; Heidenreich T; Cohen R; Schröder J
    Psychiatry Res; 2006 Jun; 142(2-3):191-9. PubMed ID: 16650902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.